Principal Investigator
Justin Watts
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240763
Clinical Trial Summary
Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and
Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid
Leukemia Patients Who Are Eligible for Intensive Induction
Chemotherapy
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
+1 (305) 2434624